Supplementary Figure S3 from Preclinical Evaluation of the Efficacy of the Cyclin-Dependent Kinase Inhibitor Ribociclib in Combination with Letrozole against Patient-Derived Glioblastoma Cells

2026 Open access

Read full text
Authors: Sidharth N. Gadgil, Aniruddha Sunil Karve, Gary A. Gudelsky, Bhavesh Babulal Gabani, Shravani Parag Kulkarni, Timothy N. Phoenix, Mario Medvedovic, David R. Plas, Trisha Michel Wise-Draper, Soma Sengupta, Biplab Dasgupta, Lalanthica Yogendran
+1 more Pankaj B. Desai
DOI: 10.1158/1535-7163.30985946
Cited by: 0

Abstract

Dose-response matrices for patient-derived GBM lines G75, G43, JHH-136 and G59 and HSA synergy model

Fields of Study & Subjects

Advanced Breast Cancer Therapies Cancer-related Molecular Pathways PARP inhibition in cancer therapy

Publication details

Publisher
American Association for Cancer Research (AACR)
Publication date
2 January 2026